Non muscle invasive bladder cancer cases initially failing to respond to bacillus Calmette-Guérin intravesical instillation therapy

Current Urology

Volumn 4, Issue 1, 2010, Pages 18-24

  Okamura, Takehiko ^a   Akita, Hidetoshi ^a   Hashimoto, Yoshihiro ^b   Tozawa, Keiichi ^b   Hinotsu, Shiro ^c   Akaza, Hideyuki ^d   Kohri, Kenjiro ^b  

^a ANJO KOSEI HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bacillus Calmette Gu rin; Failed case; Intravesical instillation; Non muscle invasive bladder cancer; Smoothed hazard

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

EID: 77953419021     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000253403     Document Type: Article

References (34)

1. Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR: Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 1986;135:265-267.
2. Soloway MS, Perry A: Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C. J Urol 1987;137:871-873.
3. Sarosdy MF, Lamm DL: Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1989; 142:719-722.
4. Cookson MS, Sarosdy MF: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol 1992;148:797-801.
5. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED: Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder cancer: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-1129.
6. Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J: Long-term follow-up of patients with stage T1 high grade transitional cell carcinoma managed by bacillus Calmette-Guérin immunotherapy. Urology 2007;69:78-82.
7. Gårdmark T, Jahnson S, Wahlquist R, Wijkström H, Malmström PU: Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int 2007;99:817-820.
8. Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT: Fatal sepsis following intravesical bacillus Calmette-Guérin administration for bladder cancer. J Urol 1990;144:1328-1330.
9. Koya MP, Simon MA, Soloway MS: Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175:2004-2010.
10. Hinotsu S, Akaza H, Ohashi Y, Kotake T: Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999;86:1818-1826.
11. Günlüsoy B, Deǧirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR: Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin. Urol Int 2005; 75:107-113.
12. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S: The increasing use of intravesical therapies for stage T1 bladdeer cancer coincides with decreasing survival after cystectomy. BJU Int 2007;100:33-36.
13. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED: Patterns of recurrence and outcomes following induction bacillus Calmette-Guérin for high risk Ta, T1 bladder cancer. J Urol 2007;177:1727-1731.
14. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205-1209.
15. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994;152:367-373.
16. Hudson MA: When intravesical measures fail. Indications for cystectomy in superficial disease. Urol Clin North Am 1992;19:601-609.
17. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL: Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987;137:220-224.
18. Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K, Kohri K: Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guérin instillation for preventing the recurrence of initially resistant superficial bladder cancers. J Urol 1996;156: 967-971.
19. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
20. Wang JL: Smoothing hazard rates: contribution to the encyclopedia of biostatistics. Version: June 22, 2003, pp1-28, http://anson.ucdavis.edu/-wang/ paper/hazardeob4.pdf .
21. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ: 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superfi-cial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161:1124-1127.
22. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M: Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761-767.
23. Herr HW, Dalbagni G: Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169:1706-1708.
24. Gallagher BL, Joudi FN, Maymi JL, O'Donnell MA: Impact of previous bacillus Calmette-Guérin failure patern on subsequent response to bacillus Calmette-Guérin plus interferon intravesical therapy. Urology 2008;71:297-301.
25. Emilliozzi P, Pansadoro A, Pansadoro V: The optimal management of T1G3 bladder cancer. BJU Int 2008;102:1265-1273.
26. Andius P, Holmäng S: Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004;93:980-984.
27. Joudi FN, O'Donnell MA: Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures. Curr Opin Urol 2004;14:271-275.
28. Karakiewicz PI, Benayoun S, Lewinshtein DJ, Chun F, Shahrour K, Perrotte P: Treatment of BCG failures with intravesical BCG/ Interferon: the University of Montreal experience. Can J Urol 2006;13:3189-3194.
29. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M: Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001;165: 1904-1907.
30. Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, Viggiani F, Ghezzi P, Nesi G, Carini M; TUR (Toscana Urologia) Group: Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int 2006;76:106-111.
31. Punnen SP, Chin JL, Jewett MA: Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 2003;10:1790-1795.
32. O'Donnell MA, Lilli K, Leopold C: Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-893.
33. Lerner S: Carcinoma in situ. AUA News 2009;14:Issue 1:1-4.
34. Okamura T, Akita H, Imura M, Kaneko T, Mizuno K, Tozawa K, Kohri K: Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment. Int J Urol 2008; 15:976-980.